We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Says Its Antibody Therapy Prevents Symptomatic COVID-19
AstraZeneca Says Its Antibody Therapy Prevents Symptomatic COVID-19
AstraZeneca said its monoclonal antibody treatment AZD7442 was shown to reduce the risk of developing COVID-19 symptoms by 77 percent vs. placebo in a phase 3 study — and it plans to use the findings to support global Emergency Use Authorizations and conditional approvals.